title: Presence of thrombin-activatable fibrinolysis inhibitor in Helicobacter pylori-associated gastroduodenal disease.
abstract: Thrombin-activatable fibrinolysis inhibitor (TAFI) plays a role in the regulation of coagulation and inflammation. In addition to inhibiting the fibrinolytic system, TAFI may also regulate the bradykinin and complement systems. We hypothesized that TAFI also plays a role in defense mechanisms of the gastric mucosa during Helicobacter pylori infection. This study comprised 65 patients with gastroduodenal disorders: 41 patients with H. pylori infection, 13 without, and 11 patients with cured H. pylori infection. The gastric intramucosal concentrations of TAFI were measured by enzyme immunoassay. The gastric levels of TAFI and plasminogen activator inhibitor-1 were significantly increased in patients with H. pylori compared to those without infection or cured H. pylori. The presence of TAFI was detected in gastric mucosal epithelial cells. The concentration of TAFI was correlated with the degree of gastric mucosal atrophy, inflammation, and disease activity. These results show that TAFI is present in the gastric mucosa and that it may play a role in the pathogenesis of H. pylori infection-associated gastroduodenal disorders.
authors.affiliation: Department of Gastroenterology and Hepatology, Mie University Graduate School of Medicine, Tsu-city, Mie, Japan.
authors.forename: Ayumi
authors.initials: A
authors.lastname: Ikeda
authors.forename: Esteban C
authors.initials: EC
authors.lastname: Gabazza
authors.forename: John
authors.initials: J
authors.lastname: Morser
authors.forename: Ichiro
authors.initials: I
authors.lastname: Imoto
authors.forename: Mikihito
authors.initials: M
authors.lastname: Kuroda
authors.forename: Corina N
authors.initials: CN
authors.lastname: D'Alessandro-Gabazza
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Hara
authors.forename: Daniel Boveda
authors.initials: DB
authors.lastname: Ruiz
authors.forename: Paloma Gil
authors.initials: PG
authors.lastname: Bernabe
authors.forename: Masaki
authors.initials: M
authors.lastname: Katsurahara
authors.forename: Masaaki
authors.initials: M
authors.lastname: Toda
authors.forename: Yoshinao
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yano
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Sumida
authors.forename: Koji
authors.initials: K
authors.lastname: Suzuki
authors.forename: Osamu
authors.initials: O
authors.lastname: Taguchi
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Takei
mesh_terms: D025901:Carboxypeptidase B2 / Q000378:metabolism*; D018932:Chemokine CCL2 / Q000378:metabolism; D004378:Duodenal Diseases / Q000378:metabolism* / Q000382:microbiology; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D005753:Gastric Mucosa / Q000378:metabolism / Q000382:microbiology; D016481:Helicobacter Infections / Q000378:metabolism* / Q000382:microbiology; D016480:Helicobacter pylori / Q000302:isolation & purification* / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D013272:Stomach Diseases / Q000378:metabolism* / Q000382:microbiology
chemical_list: C111835:CCL2 protein, human; D018932:Chemokine CCL2; D017395:Plasminogen Activator Inhibitor 1; C051321:SERPINE1 protein, human; D005340:Fibrinogen; D025901:Carboxypeptidase B2